Excalibur Fund Managers logo

Excalibur Fund Managers

Europe, England, United Kingdom, London

Description

Excalibur Fund Managers is a venture capital firm specializing in early, mid, and late stage investments.

Investor Profile

Excalibur Fund Managers has made 25 investments, with 0 in the past 12 months and 48% as lead.

Stage Focus

  • Series Unknown (28%)
  • Series B (20%)
  • Series A (16%)
  • Series D (12%)
  • Series C (12%)
  • Seed (12%)

Country Focus

  • United Kingdom (76%)
  • United States (20%)
  • Germany (4%)

Industry Focus

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Medical
  • Therapeutics
  • Wellness
  • Hospital
  • Life Science
  • Medical Device
  • Oncology
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Excalibur Fund Managers frequently co-invest with?

ABN AMRO Fund
Europe, Noord-Holland, The Netherlands, Amsterdam
Co-Investments: 2
3i Group
Europe, England, United Kingdom, London
Co-Investments: 6
Scottish Equity Partners
Europe, Glasgow City, United Kingdom, Glasgow
Co-Investments: 2
WD
Europe, Nordrhein-Westfalen, Germany, Düsseldorf
Co-Investments: 2
AB
Europe, Cambridgeshire, United Kingdom, Madingley
Co-Investments: 3
Atlas Venture
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
NV
North America, California, United States, Palo Alto
Co-Investments: 2
Apax Partners
Europe, England, United Kingdom, London
Co-Investments: 4
JPMorgan Partners
North America, New York, United States, New York
Co-Investments: 2
Alice Ventures
Europe, Lombardia, Italy, Milan
Co-Investments: 4

What are some of recent deals done by Excalibur Fund Managers?

Neurotech

Lincoln, Rhode Island, United States

Neurotech is a biotechnology company developing sight-saving therapeutics for chronic retinal diseases.

BiotechnologyHealth CareHospitalMedicalPharmaceuticalTherapeuticsWellness
Series BNov 16, 2006
Amount Raised: $35,000,000
Takeda Cambridge

Cambridge, Cambridgeshire, United Kingdom

Takeda Cambridge specializes in developing oral diabetes medications.

BiotechnologyHealth CarePharmaceutical
Series DJul 7, 2006
Amount Raised: $12,960,000
Onyvax

Bradford, Somerset, United Kingdom

Onyvax develops cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells.

BiotechnologyHealth CareTherapeutics
Series CMay 8, 2006
Amount Raised: $14,877,991
Intercytex Group

Cambridge, Cambridgeshire, United Kingdom

Intercytex Group is a biotechnology company developing cell-based therapies for the repair and regeneration of skin and hair.

BeautyBiotechnologyMedical
Series DAug 1, 2005
Amount Raised: $21,228,117
Takeda Cambridge

Cambridge, Cambridgeshire, United Kingdom

Takeda Cambridge specializes in developing oral diabetes medications.

BiotechnologyHealth CarePharmaceutical
Series UnknownJan 7, 2005
Amount Raised: $9,380,000
Cyclacel Pharmaceuticals

Berkeley Heights, New Jersey, United States

Cyclacel Pharmaceuticals develops oral therapies to treat cancers and other critical diseases.

BiotechnologyHealth CarePharmaceuticalTherapeutics
Series DJan 29, 2004
Amount Raised: $38,677,484
Plethora Solutions

Chalgrove, Oxfordshire, United Kingdom

Plethora Solutions is a pharmaceutical company that focusses on the development and marketing of products to manage urological disorders.

BiotechnologyMarketingPharmaceutical
SeedJan 1, 2004
Destination Skin

London, England, United Kingdom

Destination Skin is a skin and laser hair removal clinics in London.

BeautyCosmeticsLaser
Series UnknownJan 1, 2004
Neurotech

Lincoln, Rhode Island, United States

Neurotech is a biotechnology company developing sight-saving therapeutics for chronic retinal diseases.

BiotechnologyHealth CareHospitalMedicalPharmaceuticalTherapeuticsWellness
Series UnknownNov 24, 2003
Amount Raised: $14,133,410
Ardana Bioscience

Edinburgh, Edinburgh, City of, United Kingdom

Ardana Bioscience is a specialty pharmaceutical company.

BiotechnologyLife SciencePharmaceutical
Series BJul 30, 2003
Amount Raised: $32,360,000